Skip Nav Destination
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Issue Archive
Table of Contents
STIMULUS REPORTS
SYSTEMATIC REVIEW
CLINICAL TRIALS AND OBSERVATIONS
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
Clinical Trials & Observations
Cécile Tomowiak,on behalf of the FILO Group,Stéphanie Poulain,on behalf of the FILO Group,Charles Herbaux,on behalf of the FILO Group,Aurore Perrot,on behalf of the FILO Group,Béatrice Mahé,on behalf of the FILO Group,Pierre Morel,on behalf of the FILO Group,Thérèse Aurran,on behalf of the FILO Group,Olivier Tournilhac,on behalf of the FILO Group,Stéphane Leprêtre,on behalf of the FILO Group,Souad Assaad,on behalf of the FILO Group,Bruno Villemagne,on behalf of the FILO Group,Olivier Casasnovas,on behalf of the FILO Group,Delphine Nollet,on behalf of the FILO Group,Damien Roos-Weil,on behalf of the FILO Group,Sylvie Chevret,on behalf of the FILO Group,Véronique Leblond,on behalf of the FILO Group
HEMATOPOIESIS AND STEM CELLS
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease
Clinical Trials & Observations
Alexis Leonard,Akshay Sharma,Naoya Uchida,David Stroncek,Sandhya R. Panch,Kamille West,Eoghan Molloy,Thomas E. Hughes,Sara Hauffe,Tiffani Taylor,Courtney Fitzhugh,Jane S. Hankins,Megan Wilson,Shengdar Q. Tsai,Mitchell J. Weiss,Matthew Hsieh,John F. Tisdale
LYMPHOID NEOPLASIA
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Clinical Trials & Observations
J. J. Eertink,C. N. Burggraaff,M. W. Heymans,U. Dührsen,A. Hüttmann,C. Schmitz,S. Müller,P. J. Lugtenburg,S. F. Barrington,N. G. Mikhaeel,R. Carr,S. Czibor,T. Györke,L. Ceriani,E. Zucca,M. Hutchings,L. Kostakoglu,A. Loft,S. Fanti,S. E. Wiegers,S. Pieplenbosch,R. Boellaard,O. S. Hoekstra,J. M. Zijlstra,H. C. W. de Vet
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Stephan R. Bohl,Laura K. Schmalbrock,Imke Bauhuf,Tatjana Meyer,Anna Dolnik,Martin Szyska,Tamara J. Blätte,Sarah Knödler,Linda Röhner,Denise Miller,Miriam Kull,Christian Langer,Hartmut Döhner,Anthony Letai,Frederik Damm,Dirk Heckl,Lars Bullinger,Jan Krönke
MYELOID NEOPLASIA
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
Allison J. Kaeding,Sonali P. Barwe,Anilkumar Gopalakrishnapillai,Rhonda E. Ries,Todd A. Alonzo,Robert B. Gerbing,Colin Correnti,Michael R. Loken,Lisa Eidenschink Broderson,Laura Pardo,Quy H. Le,Thao Tang,Amanda R. Leonti,Jenny L. Smith,Cassie K. Chou,Min Xu,Tim Triche, Jr,Steven M. Kornblau,E. Anders Kolb,Katherine Tarlock,Soheil Meshinchi
SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD–mutant AML
Suruchi Pacharne,Oliver M. Dovey,Jonathan L. Cooper,Muxin Gu,Mathias J. Friedrich,Sandeep S. Rajan,Maxim Barenboim,Grace Collord,M. S. Vijayabaskar,Hannes Ponstingl,Etienne De Braekeleer,Ruben Bautista,Milena Mazan,Roland Rad,Konstantinos Tzelepis,Penny Wright,Malgorzata Gozdecka,George S. Vassiliou
PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency
Clinical Trials & Observations
Marja W. Wessels,Marjon H. Cnossen,Thamar B. van Dijk,Nynke Gillemans,K. L. Juliëtte Schmidt,Kirsten van Lom,Divya S. Vinjamur,Steven Coyne,Ryo Kurita,Yukio Nakamura,Stella A. de Man,Rolph Pfundt,Zakia Azmani,Rutger W. W. Brouwer,Daniel E. Bauer,Mirjam C. G. N. van den Hout,Wilfred F. J. van IJcken,Sjaak Philipsen
TRANSPLANTATION
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Clinical Trials & Observations
Michael Heuser,Bennet Heida,Konstantin Büttner,Clara Philine Wienecke,Katrin Teich,Carolin Funke,Maximilian Brandes,Piroska Klement,Alessandro Liebich,Martin Wichmann,Blerina Neziri,Anuhar Chaturvedi,Arnold Kloos,Konstantinos Mintzas,Verena I. Gaidzik,Peter Paschka,Lars Bullinger,Walter Fiedler,Albert Heim,Wolfram Puppe,Jürgen Krauter,Konstanze Döhner,Hartmut Döhner,Arnold Ganser,Michael Stadler,Lothar Hambach,Razif Gabdoulline,Felicitas Thol
-
Cover Image
Cover Image
COVER FIGURE
Wright-stained peripheral blood smear from a Berkeley sickle cell disease mouse that received oral FT-4202 for 2 weeks, showing a significant reduction in irreversibly sickled cells. FT-4202 is an erythrocyte pyruvate kinase inhibitor that decreases 2,3-diphosphoglycerate and increases red blood cell ATP levels to reduce sickling. See the article by Shrestha et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals